Plasma Epstein‐Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi

Point‐of‐care tools are needed in sub‐Saharan Africa (SSA) to improve pediatric Burkitt lymphoma (BL) diagnosis and treatment. We evaluated plasma Epstein–Barr virus (pEBV) DNA as a pediatric BL biomarker in Malawi. Prospectively enrolled children with BL were compared to classical Hodgkin lymphoma...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2017-06, Vol.140 (11), p.2509-2516
Main Authors: Westmoreland, Katherine D., Montgomery, Nathan D., Stanley, Christopher C., El‐Mallawany, Nader Kim, Wasswa, Peter, van der Gronde, Toon, Mtete, Idah, Butia, Mercy, Itimu, Salama, Chasela, Mary, Mtunda, Mary, Kampani, Coxcilly, Liomba, N. George, Tomoka, Tamiwe, Dhungel, Bal M., Sanders, Marcia K., Krysiak, Robert, Kazembe, Peter, Dittmer, Dirk P., Fedoriw, Yuri, Gopal, Satish
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - genetics
Burkitt lymphoma
Burkitt Lymphoma - diagnosis
Burkitt Lymphoma - pathology
Burkitt Lymphoma - virology
Cancer
Child
Deoxyribonucleic acid
DNA
DNA, Viral - genetics
Epstein-Barr virus
Epstein-Barr Virus Infections - pathology
Epstein-Barr Virus Infections - virology
Female
Herpesvirus 4, Human - genetics
Hodgkin Disease - pathology
Hodgkin Disease - virology
Hodgkin lymphoma
Humans
Lymphoma
Malawi
Male
Medical diagnosis
Medical prognosis
Medical research
Neoplasm Recurrence, Local - diagnosis
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - virology
Pediatrics
Plasma
Plasma - virology
Prognosis
Proportional Hazards Models
Prospective Studies
sub‐Saharan Africa
Viral Load - methods
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Point‐of‐care tools are needed in sub‐Saharan Africa (SSA) to improve pediatric Burkitt lymphoma (BL) diagnosis and treatment. We evaluated plasma Epstein–Barr virus (pEBV) DNA as a pediatric BL biomarker in Malawi. Prospectively enrolled children with BL were compared to classical Hodgkin lymphoma (cHL) and nonlymphoma diagnoses. Pediatric BL patients received standardized chemotherapy and supportive care. pEBV DNA was measured at baseline, mid‐treatment, and treatment completion. Of 121 assessed children, pEBV DNA was detected in 76/88 (86%) with BL, 16/17 (94%) with cHL, and 2/16 (12%) with nonlymphoma, with proportions higher in BL versus nonlymphoma (p 
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.30682